New Ray Medicine International Holding Ltd.
Hong Kong Stock ExchangeTotal Valuation
New Ray Medicine International Holding Ltd. carries a market capitalization of 41.33M, placing it among publicly traded companies globally. Its enterprise value stands at 246.33M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 41.33M |
| Enterprise Value | 246.33M |
Share Statistics
New Ray Medicine International Holding Ltd. currently has 26.02M shares outstanding.
| Shares Outstanding | 26.02M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
New Ray Medicine International Holding Ltd. trades at a trailing price-to-earnings ratio of 14.91. The price-to-sales ratio is 2.05, and the price-to-book ratio stands at 4.74.
| PE Ratio | 14.91 |
| PS Ratio | 2.05 |
| PB Ratio | 4.74 |
| P/TBV Ratio | 1.17 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
The EV/Sales ratio of 0.99 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 4.87 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.99 |
| EV / EBITDA | 4.87 |
| EV / EBIT | 4.87 |
| EV / FCF | N/A |
Financial Position
New Ray Medicine International Holding Ltd. maintains a current ratio of 9.11, meaning it holds 9.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 9.11 |
| Quick Ratio | 6.05 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
New Ray Medicine International Holding Ltd. posts a return on equity of 37.70 and a return on invested capital of 10.01.
| Return on Equity (ROE) | 37.70 |
| Return on Assets (ROA) | 9.55 |
| Return on Invested Capital (ROIC) | 10.01 |
| Return on Capital Employed (ROCE) | 37.70 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 13.68 |
Taxes
Over the trailing twelve months, New Ray Medicine International Holding Ltd. has paid 18.17M in income taxes, reflecting an effective tax rate of 34.66.
| Income Tax | 18.17M |
| Effective Tax Rate | 34.66 |
Stock Price Statistics
New Ray Medicine International Holding Ltd.'s stock has declined approximately -45.78947% over the past 52 weeks. The 50-day moving average sits at 0.21, while the 200-day moving average is 0.26.
| Beta (5Y) | N/A |
| 52-Week Price Change | -45.78947% |
| 50-Day Moving Average | 0.21 |
| 200-Day Moving Average | 0.26 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, New Ray Medicine International Holding Ltd. generated 249.04M in revenue and converted that into 34.24M in net income, yielding earnings per share of 1.80. EBITDA reached 50.55M, while operating income came in at 50.55M.
| Revenue | 249.04M |
| Gross Profit | 75.48M |
| Operating Income | 50.55M |
| Pretax Income | 52.41M |
| Net Income | 34.24M |
| EBITDA | 50.55M |
| EBIT | 50.55M |
| Earnings Per Share (EPS) | 1.80 |
Balance Sheet
Total book value stands at 107.66M, with working capital of 354.27M providing operational flexibility.
| Cash & Cash Equivalents | 264.06M |
| Total Debt | N/A |
| Net Debt | -264.06M |
| Equity (Book Value) | 107.66M |
| Book Value Per Share | 5.67 |
| Working Capital | 354.27M |
Margins
New Ray Medicine International Holding Ltd. operates with a gross margin of 30.31, reflecting its pricing power and cost economics. The operating margin of 20.30 and net profit margin of 13.75 provide insight into operational efficiency.
| Gross Margin | 30.31 |
| Operating Margin | 20.30 |
| Pretax Margin | 21.04 |
| Profit Margin | 13.75 |
| EBITDA Margin | 20.30 |
Scores
New Ray Medicine International Holding Ltd. posts an Altman Z-Score of 8.15, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 8.15 |